EIM
NPCE icon

Essex Investment Management’s Neuropace NPCE Stock Holding History

Essex Investment Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.86M Buy
217,738
+3,846
+2% +$57.7K 0.45% 87
2025
Q4 		$3.3M Sell
213,892
-2,830
-1% -$37.8K 0.5% 74
2025
Q3 		$2.23M Buy
216,722
+143,063
+194% +$1.35M 0.34% 110
2025
Q2 		$821K Sell
73,659
-64,767
-47% -$810K 0.15% 147
2025
Q1 		$1.7M Buy
+138,426
New +$1.73M 0.35% 117

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Essex Investment Management's NPCE Position: Q1 2026 in Review

Essex Investment Management increased its Neuropace (NPCE) stake by 1.8% in Q1 2026, buying an estimated $57.7K and bringing the position to 217,738 shares worth $2.86M. The position accounts for 0.45% of the portfolio, ranked #87.

Essex Investment Management first reported a position in NPCE in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.3M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Essex Investment Management held 217,738 shares of Neuropace worth $2.86M as of Q1 2026.
  • Essex Investment Management bought 3,846 Neuropace shares in Q1 2026, an estimated $57.7K.
  • Neuropace made up 0.45% of Essex Investment Management's portfolio in Q1 2026, its #87 holding.
  • Essex Investment Management first reported a position in Neuropace in Q1 2025 and has held it in 5 quarters since.
  • Essex Investment Management's Neuropace position peaked at $3.3M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Essex Investment Management's 13F filing for Q1 2026, filed 11 May 2026.